Skip to main content

Corcept Therapeutics Incorporated

corporate_fare Company Profile

Corcept Therapeutics Incorporated

CORT·NASDAQ·Life Sciences·CIK 0001088856

We are a commercial-stage company focused on discovering and developing medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders by adjusting the effects of the hormone cortisol. Cortisol is crucial for the body's stress response, metabolism, immune system, and emotional stability, with levels naturally peaking upon awakening and decreasing throughout the day. We address both insufficient cortisol activity, which can cause dehydration, hypotension, shock, fatigue, and hypoglycemia, and excessive cortisol activity, known as hypercortisolism. Hypercortisolism can lead to hypertension, diabetes, impaired glucose tolerance, obesity, fatty liver disease, depressed mood, psychosis, wasting of limbs, edema, fatigue, and insomnia. Cortisol also impacts cancer by reducing immune response to oncogenesis, protecting certain cancer cells from chemotherapy, and promoting the growth of others. Pre-clinical and clinical data suggest that modulating cortisol activity may improve outcomes for patients with fatty liver disease and metabolic dysfunction-associated steatohepatitis ("MASH"), which can lead to liver fibrosis and cirrhosis. Data also indicate potential treatments for patients with amyotrophic lateral sclerosis ("ALS") through cortisol modulation. Since 2012, we have marketed Korlym in the United States for treating hypercortisolism (Cushing's syndrome). In June 2024, we launched an authorized generic version of Korlym for the same condition. Korlym's active ingredient, mifepristone, works by competing with cortisol for binding to the glucocorticoid receptor ("GR"), effectively modulating the effects of abnormal cortisol levels and release patterns without disrupting healthy cortisol functions or rhythms.

Corcept Therapeutics Incorporated (NASDAQ:CORT) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 25 items for CORT at importance 7 or higher on its 1–10 market-impact scale.

Recent high-impact activity:

  • Corcept Therapeutics Incorporated Securities Fraud Class Action Result of FDA Approval Issues and 50% Stock Decline - Investors may Contact Lewis Kahn, Esq, at Kahn Swick & Foti, LLC
  • Corcept Therapeutics Faces Major Setbacks: FDA Rejects Relacorilant, Key Patent Lost, and Profitability Declines
  • Corcept Reports Mixed 2025 Results, Sets PDUFA for Ovarian Cancer Drug, Advances ALS & MASH Pipeline
  • Corcept Loses Federal Circuit Patent Appeal Against Teva for Key Drug Korlym
  • Corcept's Phase 3 ROSELLA Trial Meets Overall Survival Endpoint in Platinum-Resistant Ovarian Cancer

Financial Snapshot

Fiscal year ended December 31, 2025
Revenue
$761.41M
Net Income
$99.65M
Diluted EPS
$0.82
Op. Cash Flow
$142M
Free Cash Flow
$141.78M
Gross Profit
$748.43M
Operating Income
$44.8M
Cash & Equivalents
$120.5M
Debt / Equity
0.00×
Net Margin
13.1%
Shares Outstanding
105.97M sh
Source: 10-K · filed 2026-02-24 · accession 0001628280-26-011091
$63.62
52-week range · as of 2026-11-03 $28.66 – $126.38
Market cap
$6.96B
Volume
1.1M (1.0× avg)
3-mo avg 1.1M
Live data · 2026-11-22 12:47 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed CORT - Filings & News (Page 2)

CORT
Feb 26, 2026, 9:25 PM EST
Source: Acceswire
Importance Score:
7
Price at Filing: $35.78
Real-time Price: $63.62 info
Change: +$27.84 (+78%) info
Market Cap: $6.963B info
CORT
Feb 24, 2026, 4:13 PM EST
Filing Type: 10-K
Importance Score:
9
Price at Filing: $35.10
Real-time Price: $63.62 info
Change: +$28.52 (+81%) info
Market Cap: $6.963B info
CORT
Feb 24, 2026, 4:10 PM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $35.10
Real-time Price: $63.62 info
Change: +$28.52 (+81%) info
Market Cap: $6.963B info
CORT
Feb 19, 2026, 4:38 PM EST
Filing Type: 8-K
Importance Score:
9
Price at Filing: $33.56
Real-time Price: $63.62 info
Change: +$30.06 (+90%) info
Market Cap: $6.963B info
CORT
Jan 22, 2026, 8:10 AM EST
Filing Type: 8-K
Importance Score:
9
Price at Filing: $45.00
Real-time Price: $63.62 info
Change: +$18.62 (+41%) info
Market Cap: $6.963B info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets